Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through…
By R. Maki, J. Wathen, Shreyaskumar R Patel, D. Priebat, S. Okuno, B. Samuels, M. Fanucchi, D. Harmon, S. Schuetze, D. Reinke and 4 more. Journal of Clinical Oncology, 2007
643 citations recorded by the source corpus.
Subfields: Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/f43a6f2accdcd0ef476664ce83f74835c903295e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Application of Bayesian Approach in Cancer Clinical Trial (2014, background): “Recently, the oncology trial result through Bayesian approach has been published [1].”
- Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2018, result): “• One trial showed that gemcitabine/docetaxel is more effective than gemcitabine alone as second-line ChT, with special reference to LMS and undifferentiated pleomorphic sarcoma, but these data have not been confirmed (equivalence in response rate, PFS and OS) in a second randomised trial conducted ”